Matteo Lambertini, Associate Professor at the University of Genova, shared on X:
“Oral abstract Breast Cancer session at ESMO26: impressive data from APEXbreast01 trial showing benefit for Rolditamig Deuderuxtecan as first line chemotherapy in advanced HER2-low metastatic disease.”
To which, Kristina Jankovic, Medical Oncology Resident at University Clinical Center Nis, added:
“Impressive APEXBreast01 data showing benefit with rolditamig deuderuxtecan over first-line chemotherapy in HR+/HER2-low metastatic Breast Cancer!
- mPFS: 16.4 vs 5.5 months (HR 0.29)
- ORR more than doubled
- Encouraging early OS trend.”
You can also read: APEX-Breast01: TQB2102 Cuts Progression Risk by 71% in HER2-Low Advanced Breast Cancer.
